Proscaline
Proscaline is a lesser-known psychedelic of the substituted phenethylamine class, structurally related to mescaline as its 4-propyloxy analog.citation needed Its synthesis was first published by David E. Nichols in 1977, and it was later evaluated by Alexander Shulgin, who estimated its potency at roughly five times that of mescaline. Shulgin documented his findings in the 1991 book PiHKAL. It belongs to a series of mescaline analogs including escaline and allylescaline,1 and appeared on the research chemical market in the 2010s.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Proscaline produces a gentle, mescaline-like psychedelic state that develops fully within the first couple of hours and can sustain a warm, contented euphoria for the remainder of the day. The experience is frequently described as pleasant but low-key, with a peaceful, sociable character rather than a deep or revelatory one; at common doses some users find it notably uneventful. Toward the upper end of the dosage range the balance shifts toward physical load and irritability, and sleep may remain impossible for twelve hours or more, though no hangover is reported the following day.
Physical
The body load includes mild mental and physical stimulation with restlessness and occasional tremor during the come-up, alongside muscle tension, pupil dilation, appetite suppression, and sweating or chills. Pronounced wakefulness is typical, and insomnia can persist well past the peak; some users instead report drowsiness as lower-dose experiences wind down.
Cognitive
The headspace is characterized by deep peace, contentment, and a steadily building euphoria, with strong sociability and a light, joking conversational tone. Mental clarity is largely preserved even when the body feels intoxicated, but the state tends to lack enhanced clarity, deep realizations, or motivation for serious analysis, and confusion or irritability can appear, particularly at higher doses.
Emotional
Visual
Visuals are present with eyes open and closed but remain relatively subtle at common doses, with color brightening as the most consistent feature.
Tactile
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
Proscaline acts as a serotonin 5-HT2 receptor agonist with activity at the 5-HT2A, 5-HT2B, and 5-HT2C receptors.2 It has been described as a partial agonist at the 5-HT2A receptor, activation of which is thought to be responsible for its psychedelic effects. Notably, proscaline displays considerably greater potency at the 5-HT2C receptor compared to the 5-HT2A or 5-HT2B receptors.2
Pharmacokinetics
Proscaline is considerably more lipophilic than mescaline or escaline (log P of 1.70 compared to 0.78 and 1.11, respectively), a property expected to favor blood-brain barrier permeability.3
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowProscaline is described as non-habit-forming, and interest in using it may diminish with repeated use. Its use is most often characterized as self-regulating.
History & Culture
Proscaline was first synthesized and investigated by Czech chemist Otakar Leminger in 1972.citation needed The compound was subsequently synthesized by David E. Nichols, who published his work in the Journal of Medicinal Chemistry in 1977. Around this period, Alexander Shulgin independently…
Legality
International
Proscaline, 4-propoxy-3,5-dimethoxyphenethylamine, and 4-propoxy-3,5-DMPEA do not appear in the current INCB Yellow List for the 1961 Convention, the INCB Green List for the 1971 Convention, or Tables I and II of the 1988 Convention.
By Country
References
Source Pages
Bluelight: Proscaline Discussion
Erowid Experience Vault: Fully Psychedelic in the Most Subtle of Ways
Erowid Experience Vault: Mind Candy (50mg)
Erowid Experience Vault: Nothing Extreme (102mg)
Erowid: Proscaline Experience Vault
Isomer Design (TiHKAL/PiHKAL)
Isomer Design PiHKAL #140: Proscaline
PsychonautWiki
TripSit Factsheets
Wikipedia
Citations
- Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, & Matthias E. Liechti. (2021). Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines. Front Pharmacol, 12. https://doi.org/10.3389/fphar.2021.7942541
- Jason Wallach, Andrew B. Cao, Maggie M. Calkins, Andrew J. Heim, Janelle K. Lanham, Emma M. Bonniwell, Joseph J. Hennessey, Hailey A. Bock, Emilie I. Anderson, Alexander M. Sherwood, Hamilton Morris, Robbin de Klein, Adam K. Klein, Bruna Cuccurazzu, James Gamrat, Tilka Fannana, Randy Zauhar, Adam L. Halberstadt, & John D. McCorvy. (2023). Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nature Communications. https://doi.org/10.1038/s41467-023-44016-112
- Adam L Halberstadt, Muhammad Chatha, Stephen J Chapman, & Simon D Brandt. (March 2019). Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. J Psychopharmacol, 33(3), 406–414. https://doi.org/10.1177/02698811198266101
- Neue-psychoaktive-Stoffe-Gesetz (NpSG) — Inkrafttreten und Anlage 1 (Von 2-Phenethylamin abgeleitete Verbindungen). Bundesamt für Justiz (2016). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html12
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html1
- § 3 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__3.html1
- Opiumwet. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/2025-07-011
- Forskrift om narkotika (narkotikaforskriften). lovdata.no (n.d.). https://lovdata.no/dokument/SF/forskrift/2013-02-14-199/KAPITTEL_1-11
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2023/1939/text.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Proscaline article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.